December 20, 2017 10:10 AM ESTUpdated May 26, 08:50 PM
Financing
Startups
Cell/Gene Tx

In gene ther­a­py's sec­ond big win this week, Or­chard nabs $110M Se­ries B

Brittany Meiling

Lon­don start­up Or­chard Ther­a­peu­tics is join­ing the ranks of com­mer­cial-stage gene ther­a­py com­pa­nies with a new $110 mil­lion Se­ries B round to take its lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times